According to Zacks, “Brenntag AG engages in the production and distribution of chemicals. It operates through the North America, Latin America, EMEA and Asia Pacific segments. Brenntag AG is headquartered in Mülheim an der Ruhr, Germany. “
Separately, ValuEngine downgraded Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 17th.
Shares of BNTGY opened at $10.32 on Monday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.21 and a current ratio of 1.76. BRENNTAG AG/ADR has a 1 year low of $8.20 and a 1 year high of $12.86. The firm’s 50 day moving average is $9.69. The stock has a market cap of $7.97 billion, a price-to-earnings ratio of 14.74, a P/E/G ratio of 1.63 and a beta of 1.27.
BRENNTAG AG/ADR (OTCMKTS:BNTGY) last announced its quarterly earnings data on Thursday, May 9th. The company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.16. The business had revenue of $3.70 billion during the quarter. BRENNTAG AG/ADR had a net margin of 3.61% and a return on equity of 14.00%. As a group, equities research analysts expect that BRENNTAG AG/ADR will post 0.66 EPS for the current year.
About BRENNTAG AG/ADR
Brenntag AG, a chemical distribution company, purchases and supplies industrial and specialty chemicals in Europe, the Middle East, Africa, North America, Latin America, the Asia Pacific, and internationally. The company also provides value added services. It serves customers in various end-market industries, such as adhesives, paints, oil and gas, food, water treatment, personal care, and pharmaceuticals.
Read More: Bollinger Bands
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BRENNTAG AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRENNTAG AG/ADR and related companies with MarketBeat.com's FREE daily email newsletter.